Trust Signals
Evidence base: Phase 2 RCT (NEJM, Jastreboff et al. 2023), FDA FDCA compounding statutes, USP peptide standards.
Conflicts: FormBlends does not sell retatrutide. We have no financial relationship with Eli Lilly.
Last updated: 2026-05-29. Regulatory status can change; verify with FDA.gov before acting.
Key Takeaways
- Retatrutide (LY3437943) is not FDA approved as of mid-2025. Legal access pathways are narrow: clinical trials, compounding pharmacy prescription, or compassionate use.
- Phase 2 data (Jastreboff et al., NEJM 2023, n=338) showed roughly 17.5 percent mean weight loss at 48 weeks on 12 mg weekly, the largest single-arm result published for any GLP-1-class peptide at that time point.
- Retatrutide's third receptor target, the glucagon receptor, is the mechanistic feature that separates it from semaglutide and tirzepatide. It is also the feature most commonly misrepresented by vendors.
- Research peptide vendors operate in a legal gray zone. Independent purity audits of the broader research peptide market have found significant batch-to-batch variation. A COA from an ISO-accredited third-party lab is the minimum acceptable evidence.
- The FDA's TRIUMPH Phase 3 program is actively recruiting. Clinical trial enrollment is free, provides the drug at no cost, and is the only route with pharmacovigilance monitoring.
How to Get Reta Peptide: Direct Answer
How to get reta peptide depends entirely on your jurisdiction and risk tolerance. In the United States, the three legitimate routes are enrolling in a Eli Lilly TRIUMPH Phase 3 trial on ClinicalTrials.gov, obtaining a compounded version via a licensed physician and 503A pharmacy, or applying for compassionate use. Retatrutide is not FDA approved, so no commercial prescription product exists.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is retatrutide, exactly?
- Is retatrutide legal to obtain?
- How do I join a retatrutide clinical trial?
- Can a compounding pharmacy provide it?
- What about research peptide vendors?
- Evidence ledger: what the data actually shows
- Mechanism with numbers: how retatrutide works
- What most pages get wrong about reta peptide
- Honest head-to-head: retatrutide vs. tirzepatide vs. semaglutide
- Operational guide: reading a COA and reconstituting safely
- FAQ
- Sources
What Is Retatrutide, Exactly?
Retatrutide is a synthetic acylated peptide developed by Eli Lilly under the internal designation LY3437943. It is a triple incretin receptor agonist, meaning it activates three distinct G-protein-coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple agonism is the core pharmacological claim that distinguishes it from both semaglutide (GLP-1R only) and tirzepatide (GLP-1R and GIPR).
The peptide backbone shares structural elements with native glucagon, GLP-1, and GIP but is modified with a C18 fatty diacid chain that enables once-weekly subcutaneous dosing by extending its half-life through albumin binding. This is the same fatty acid tethering strategy Lilly used with tirzepatide and Novo Nordisk used with semaglutide.
Is Retatrutide Legal to Obtain?
Under the Federal Food, Drug, and Cosmetic Act, a drug cannot be legally marketed or commercially dispensed without FDA approval. Retatrutide sits outside that approval. The legal access options that do exist are:
- Clinical trial enrollment: Participants receive the drug under an Investigational New Drug (IND) exemption held by Eli Lilly. This is the cleanest legal pathway.
- 503A compounding: A licensed pharmacy may compound retatrutide for an individually identified patient based on a valid practitioner prescription. The active pharmaceutical ingredient (API) must come from an FDA-registered supplier. The finished compound is not FDA-approved.
- 503B outsourcing facilities: May produce retatrutide in larger quantities without patient-specific prescriptions, but only if the compound is on the FDA's 503B bulks list. Verify current list status at FDA.gov before assuming this applies.
- Compassionate use / expanded access: Requires an application to both the FDA and Eli Lilly. Approvals are rare and typically require exhaustion of other treatment options.
Purchasing injectable retatrutide directly from a research chemical vendor for self-administration does not fit cleanly into any of the above categories. The FDA has issued warning letters to companies marketing injectable peptides without approval, and enforcement risk exists for both vendors and, in theory, importers.
How Do I Join a Retatrutide Clinical Trial?
Eli Lilly's Phase 3 program is named TRIUMPH. It encompasses multiple sub-studies targeting different populations: people with obesity without diabetes, people with type 2 diabetes, people with metabolic-associated steatohepatitis (MASH), and people with cardiovascular disease. To find open studies:
- Go to ClinicalTrials.gov and search "retatrutide" or "LY3437943."
- Filter status to "Recruiting" and country to your location.
- Review inclusion criteria carefully. Common requirements include a BMI at or above a specified threshold (typically 27 or 30, depending on the sub-study), certain HbA1c ranges for diabetes studies, and exclusion of prior GLP-1 receptor agonist use within a set window.
- Contact the listed study coordinator directly. Eli Lilly also maintains a patient-finder tool at LillyTrials.com.
Clinical trial participation is free. You receive the investigational drug at no cost, undergo regular clinical monitoring, and are covered under the trial's indemnification. The tradeoff: you may be randomized to placebo for part of the trial, and you must commit to regular clinic visits.
Can a Compounding Pharmacy Provide Retatrutide?
Yes, with important caveats. A physician can write a prescription for compounded retatrutide for an identified patient. A 503A pharmacy licensed in your state can then compound it. The practical constraints are:
- The pharmacy must source API from an FDA-registered facility. Ask for the supplier's Drug Master File (DMF) or FDA registration number.
- The compound must be prepared for a specific patient, not produced in bulk for general sale without a 503B designation.
- No finished product receives FDA review for efficacy, safety, or purity. The physician and pharmacist carry the liability.
- Cost is paid out of pocket in most cases. Expect significant variation in pricing across pharmacies.
Telehealth platforms prescribing compounded GLP-1 class peptides expanded rapidly after semaglutide and tirzepatide shortages. Some now offer compounded retatrutide. The quality and compliance of these services vary substantially. Ask any prescriber to confirm the compounding pharmacy's 503A or 503B status and request a third-party COA for every batch.
What About Research Peptide Vendors?
This is the section most pages skip because it is commercially inconvenient. Research peptide vendors sell retatrutide labeled "for research use only, not for human consumption." In practice, a significant portion of buyers administer these products to themselves. Several realities apply:
- Purity is not guaranteed. Academic and independent assays of research peptide vendor products have found purity figures, concentrations, and even identity mismatches. A vial labeled "retatrutide 10 mg" may contain a different amount, a related but different peptide, or additional unidentified substances.
- No sterility standard is legally required for research-labeled injectables in the same way USP 797 governs compounding pharmacies. Bacterial endotoxin contamination from gram-negative bacteria can cause fever and systemic inflammation.
- No pharmacovigilance. If you have a serious adverse event, there is no reporting mechanism. The vendor has no legal obligation to track adverse events or report to the FDA.
- Regulatory risk. The FDA has issued warning letters to specific research peptide companies and has the authority to seize products. Enforcement patterns have increased since 2023.
This page does not endorse purchasing from research vendors. The information above is provided so that readers who are weighing their options can do so with accurate information about the actual risk profile.
Evidence Ledger: What the Data Actually Shows
| Claim | Best Evidence Type | Key Source | Effect Direction | Confidence |
|---|---|---|---|---|
| Retatrutide reduces body weight vs. placebo | Phase 2 RCT, n=338, 48 weeks | Jastreboff et al., NEJM 2023 | Positive (roughly 17.5% at highest dose) | Moderate (Phase 2 only; Phase 3 pending) |
| Triple receptor agonism (GLP-1, GIP, GCGR) | In vitro binding and cellular assay | Eli Lilly preclinical disclosures | Confirmed mechanism | High (mechanism confirmed; clinical relevance of GCGR component still under study) |
| Reduces liver fat in metabolic liver disease | Phase 2 sub-analysis | Jastreboff et al., NEJM 2023; secondary endpoints | Positive signal | Low to Moderate (underpowered for this endpoint in Phase 2) |
| Cardiovascular event reduction | No dedicated CVOT completed | Phase 3 TRIUMPH-CVOT planned | Unknown | Very Low (extrapolation from class effects only) |
| Muscle mass preservation during weight loss | Animal model and preliminary human data | Preclinical rodent studies | Possible benefit | Very Low |
| Gastrointestinal adverse events (nausea, vomiting) | Phase 2 RCT | Jastreboff et al., NEJM 2023 | Dose-dependent increase vs. placebo | High |
Mechanism With Numbers: How Retatrutide Works
Retatrutide activates three receptor systems. Here is what each contributes, and what the numbers do and do not prove:
- GLP-1R agonism: Slows gastric emptying, enhances glucose-dependent insulin secretion, and reduces appetite by acting on hypothalamic and brainstem circuits. This is the mechanism shared with semaglutide and tirzepatide. GLP-1R agonism accounts for the majority of the nausea side effect profile.
- GIPR agonism: Also enhances glucose-dependent insulin secretion and may potentiate GLP-1R-mediated appetite suppression. The GIPR component appears to reduce GI side effects relative to pure GLP-1R agonism at equivalent efficacy doses. This hypothesis has mechanistic support from tirzepatide data but is not directly proven for retatrutide alone.
- GCGR agonism: Increases hepatic glucose output (counterintuitive in a metabolic drug), but at the doses and ratio used in retatrutide, the net effect is increased energy expenditure and accelerated hepatic fat oxidation. In rodent studies, GCGR agonism drives thermogenic gene expression in brown adipose tissue. Whether this translates to meaningful thermogenesis in humans at retatrutide's clinical doses is not definitively established in published human data.
The Phase 2 trial tested weekly subcutaneous doses from 1 mg up to 12 mg, with a multi-step titration starting at 2 mg. The half-life based on fatty acid albumin binding is consistent with once-weekly dosing (similar to tirzepatide at roughly 5 days). The molecular weight of retatrutide is approximately 4700 daltons, which is relevant for COA verification (see label literacy section below).
What the mechanism does NOT prove: GCGR agonism in isolation raises blood glucose. Retatrutide's overall glucose-neutral to glucose-lowering effect in the trial depends on the specific ratio of all three agonist activities. Extrapolating GCGR effects from other drugs or from higher doses is not valid.
What Most Pages Get Wrong About Reta Peptide
Most articles describing how to get reta peptide either omit inconvenient facts or misrepresent the evidence. Here is what they consistently skip:
- The 17.5 percent figure is a mean, not a guarantee. In Phase 2, there was substantial individual variation. Some participants in the highest-dose arm lost considerably more. Others lost less or discontinued due to side effects. Means from a 338-person Phase 2 trial should not be presented as a reliable individual outcome.
- Compounded retatrutide is not the same as the Lilly clinical product. Lilly's drug uses a proprietary formulation and excipient package validated through GMP manufacturing. Compounded versions use different excipients and have not undergone bioequivalence testing. Whether the pharmacokinetics are identical is unknown.
- The glucagon receptor claim is often overstated. Vendors and wellness clinics frequently cite GCGR agonism as proof of superior fat burning or muscle preservation. The human evidence for these specific outcomes from GCGR activity in retatrutide is preliminary. The mechanism is real. The clinical magnitude in humans is not yet quantified.
- Phase 3 results could change the picture. Phase 2 trials regularly show larger effects than Phase 3 due to smaller sample sizes, more controlled populations, and publication bias. Phase 3 TRIUMPH results will be the true basis for approval and clinical use. Do not anchor on Phase 2 numbers as if they are final.
- Weight regain after stopping is not discussed by most sources. Data from GLP-1 class drugs consistently show significant weight regain after discontinuation. There is no reason to believe retatrutide will differ mechanistically. This is a lifetime-management consideration, not a short course.
Honest Head-to-Head: Retatrutide vs. Tirzepatide vs. Semaglutide
| Factor | Retatrutide | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|---|
| FDA approval status | Not approved (Phase 3) | Approved (obesity, T2D) | Approved (obesity, T2D, CV risk) |
| Receptor targets | GLP-1, GIP, GCGR | GLP-1, GIP | GLP-1 only |
| Best published weight loss (mean) | Roughly 17.5% at 48 weeks (Phase 2) | Roughly 20.9% at 72 weeks (Phase 3, SURMOUNT-1) | Roughly 14.9% at 68 weeks (Phase 3, STEP 1) |
| Cardiovascular outcomes trial | None completed | SURMOUNT-MMO ongoing; SELECT (sema class) | SELECT trial: 20% CV event reduction |
| Dosing frequency | Once weekly (Phase 2 protocol) | Once weekly | Once weekly |
| Legal prescribability | Compounding only, no approved product | Standard prescription | Standard prescription |
| Long-term safety data | 48 weeks Phase 2 only | Multiple years post-approval | Multiple years post-approval |
| Where retatrutide loses clearly | Regulatory standing, safety database, access, insurance | Narrowly ahead on published weight loss at longer duration | Strongest cardiovascular outcome data |
Bottom line: If you have access to tirzepatide or semaglutide and they are appropriate for you, the evidence base for those drugs is substantially larger and they carry a real regulatory approval. Retatrutide's potential advantage is a modestly larger or faster weight-loss signal in early data and possibly a hepatic fat reduction benefit, but neither is proven at Phase 3 scale. The choice to pursue a non-approved compound carries real trade-offs that approved alternatives do not.
Operational Guide: Reading a COA and Reconstituting Safely
If you are working with compounded retatrutide, the following practical standards apply regardless of source:
Certificate of Analysis (COA) Checklist
| COA Element | Minimum Acceptable Standard | Red Flag |
|---|---|---|
| HPLC purity | Greater than or equal to 98% | Below 95%, or no HPLC data |
| Molecular weight confirmation | Mass spec result consistent with roughly 4700 Da for retatrutide | No mass spec data, or significant deviation |
| Endotoxin testing | Below USP limit for parenteral products (varies by dose; typically less than 5 EU/kg/hr) | No endotoxin data |
| Sterility (for injectables) | USP 71 sterility test passed | No sterility test |
| Testing laboratory | ISO 17025-accredited third-party lab, named on COA | In-house lab, unnamed lab, or lab with no verifiable accreditation |
| Lot number and date | Present and cross-referenced | Absent, generic, or not batch-specific |
Storage and Reconstitution Essentials
Lyophilized (freeze-dried) retatrutide peptide should be stored at 2 to 8 degrees Celsius before reconstitution. The reason: peptide chains undergo hydrolysis and beta-sheet aggregation at higher temperatures. Water molecules catalyze peptide bond cleavage, and the lyophilized state dramatically slows this by removing the aqueous environment. This is why temperature excursions during shipping are a real concern, not a minor inconvenience.
To reconstitute, inject bacteriostatic water slowly down the side of the vial rather than directly onto the lyophilized cake. Gentle swirling, not shaking, is used because vigorous agitation promotes aggregation of peptide chains into inactive oligomers. Once reconstituted, store at 2 to 8 degrees Celsius and use within 28 days as a conservative standard. Avoid repeated freeze-thaw cycles; each cycle increases the probability of aggregation and loss of potency.
A degraded solution often appears cloudy or shows visible particulate matter. Do not inject a solution with either of these characteristics. A slight yellow tint from the bacteriostatic preservative is normal, but cloudiness is not.
Concentration math: if you have a 10 mg vial reconstituted with 2 mL of bacteriostatic water, each 0.1 mL (a typical insulin syringe unit at 100 units/mL) contains 0.5 mg. For a 2 mg dose, you would draw 0.4 mL. Verify your own calculation before every injection. Dosing errors in high-potency peptides are the most common preventable harm in self-administration contexts.
FAQ
How to get reta peptide legally in the United States?
As of mid-2025, retatrutide has not received FDA approval. Legal access options are limited to: enrolling in an active Eli Lilly clinical trial, obtaining a physician-supervised compounded version from a licensed 503A or 503B pharmacy, or participating in a named-patient expanded access program if Lilly grants compassionate use. Purchasing raw peptide from research chemical vendors exists in a legal gray zone and carries significant purity and safety risks.
What is retatrutide and how does it differ from semaglutide or tirzepatide?
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Semaglutide is a single GLP-1 agonist. Tirzepatide is a dual GLP-1 and GIP agonist. Retatrutide's glucagon receptor activity adds thermogenic and hepatic fat-reduction effects not seen with the other two, which may explain the larger weight-loss percentages observed in Phase 2 trials.
Is retatrutide FDA approved?
No. As of mid-2025, retatrutide remains in Phase 3 clinical trials. It does not have FDA approval for any indication. This means it cannot be legally marketed, dispensed without a valid prescription in a compounding context, or promoted with efficacy claims in the United States.
Can a doctor prescribe retatrutide right now?
Physicians cannot prescribe an FDA-approved retatrutide product because none exists. However, compounding pharmacies operating under FDCA Section 503A may prepare retatrutide for an identified patient based on a practitioner's prescription, provided the API is sourced from an FDA-registered facility. This is legally distinct from an approved prescription and carries more physician liability.
How do I find an active retatrutide clinical trial?
Search ClinicalTrials.gov using the term "retatrutide" or "LY3437943" and filter by status "Recruiting." Eli Lilly's TRIUMPH Phase 3 program contains multiple sub-trials for obesity, type 2 diabetes, and metabolic-associated steatohepatitis. Eligibility criteria typically include BMI thresholds, HbA1c ranges, and cardiovascular history. Enrollment is free and participants receive the drug at no cost.
What are the risks of buying retatrutide from a research peptide vendor?
Independent third-party analyses of research peptide vendors have found purity, identity, and concentration variability. Risks include incorrect dosing from miscalibrated vials, peptide fragments from poor synthesis, undisclosed excipients, microbial contamination, and no pharmacovigilance if an adverse event occurs. There is also regulatory risk: the FDA has issued warning letters to vendors selling injectable peptides to individuals.
What did the Phase 2 retatrutide trial actually show?
The Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) enrolled 338 adults with obesity. At 48 weeks, the highest-dose group (12 mg weekly) achieved a mean body weight reduction of approximately 17.5 percent from baseline, compared to 1.6 percent with placebo. Nausea, vomiting, and diarrhea were the most common adverse events, predominantly mild to moderate.
How is retatrutide dosed and administered?
In the Phase 2 trial, retatrutide was administered as a once-weekly subcutaneous injection. Doses ranged from 1 mg to 12 mg, with titration schedules over several weeks to minimize gastrointestinal side effects. The 12 mg dose delivered the largest weight loss. Final dosing protocols may change based on Phase 3 results.
How do I verify the purity of a compounded or research retatrutide product?
Request a Certificate of Analysis (COA) from the supplier. A trustworthy COA shows HPLC purity above 98 percent, mass spectrometry confirmation of the correct molecular weight (roughly 4700 daltons for retatrutide), endotoxin testing below USP limits, and sterility testing. COAs from unverifiable in-house labs carry much less weight than those from ISO-accredited third-party labs.
What should I know about storing and reconstituting retatrutide peptide?
Lyophilized retatrutide peptide is generally stored at 2 to 8 degrees Celsius. After reconstitution with bacteriostatic water, most protocols recommend use within 28 to 30 days refrigerated and to avoid repeated freeze-thaw cycles. UV light and heat accelerate beta-sheet aggregation and disulfide scrambling in peptide chains, degrading potency. Do not use if the solution appears cloudy or contains visible particles.
How does retatrutide compare to tirzepatide for weight loss?
Phase 2 data for retatrutide showed approximately 17.5 percent mean weight loss at 48 weeks at the highest dose. Tirzepatide's SURMOUNT-1 Phase 3 trial (Jastreboff et al., 2022) showed up to approximately 20.9 percent mean weight loss at 72 weeks at the 15 mg dose. Direct comparison is limited because trial durations, populations, and titration schedules differ. Tirzepatide has a longer track record and is FDA approved.
Will retatrutide be covered by insurance when approved?
Coverage is not determinable before FDA approval. The precedent set by semaglutide and tirzepatide suggests variable coverage: Medicare Part D covers these drugs for cardiovascular indications but has historically excluded obesity-only indications. The Treat and Reduce Obesity Act, if passed, could expand coverage. Expect a similar debate for retatrutide if approved for obesity.
Sources
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity -- A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. PMID: 37366315.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. PMID: 35658024.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002. PMID: 33567185.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. 2023;389(24):2221-2232. PMID: 37952131.
- U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov. Accessed 2025.
- U.S. Food and Drug Administration. Human Drug Compounding: 503A and 503B Distinctions. FDA.gov. Accessed 2025.
- ClinicalTrials.gov. Search: LY3437943. National Library of Medicine. Accessed 2025.
- United States Pharmacopeia. USP Chapter 797: Pharmaceutical Compounding -- Sterile Preparations. USP-NF. Current edition.
- U.S. Food and Drug Administration. Warning Letters: Research Peptide Companies. FDA.gov. Various dates, 2023 to 2025.
- Finan B, Ma T, Ottaway N, et al. Unimolecular
Related peptide guides